|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||151.50 - 151.50|
|52 Week Range||97.93 - 162.00|
|Beta (3Y Monthly)||0.58|
|PE Ratio (TTM)||64.77|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Sartorius Stedim Biotech SA (EPA:DIM), with a market cap of €8.7b, are often out of Read More...
Sartorius Stedim Biotech (SSB) (DIM.PA), a leading international supplier of the biopharmaceutical industry, and Lonza announced today that they have modified their current agreement for supply of cell culture media by mutual accord. The agreement, signed in 2012, gave SSB exclusive sales and marketing rights for certain cell culture media and buffers developed and manufactured by Lonza for use in biopharmaceutical manufacturing processes.
With a market capitalization of €9.8b, Sartorius Stedim Biotech SA (EPA:DIM) is a large-cap stock, which is considered by most investors as a safe bet. Common characteristics for these big Read More...
When Sartorius Stedim Biotech SA (EPA:DIM) announced its most recent earnings (30 June 2018), I did two things: looked at its past earnings track record, then look at what is Read More...
The big shareholder groups in Sartorius Stedim Biotech SA (EPA:DIM) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owningRead More...